Company Description
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia.
The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.
It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials.
Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
| Country | United States |
| Founded | 1992 |
| IPO Date | Aug 11, 2016 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 5,900 |
| CEO | Dr. August James Troendle M.D. |
Contact Details
Address: 5375 Medpace Way Cincinnati, Ohio 45227 United States | |
| Phone | (513) 579-9911 |
| Website | medpace.com |
Stock Details
| Ticker Symbol | MEDP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001668397 |
| CUSIP Number | 58506Q109 |
| ISIN Number | US58506Q1094 |
| Employer ID | 32-0434904 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Dr. August James Troendle M.D. | Chairman and Chief Executive Officer |
| Jesse J. Geiger BBA, CPA | President |
| Kevin M. Brady | Chief Financial Officer and Treasurer |
| Susan E. Burwig BSN, MA | Executive Vice President of Operations |
| Stephen P. Ewald J.D. | Chief Compliance Officer, General Counsel and Corporate Secretary |
| Brandon Ebken | Chief Information Officer |
| Lauren Morris | Associate Director of Investors Relations |
| Todd Meyers | Vice President of Business Development and Marketing |
| John T. Wynne MBA | Senior Vice President of Commercial Operations and Clinical Pharmacology Unit |
| Reinilde Heyrman M.D. | Chief Medical Officer of Medical Department |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 3, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 3, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 3, 2024 | ARS | Filing |
| Mar 29, 2024 | 8-K | Current Report |
| Mar 20, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 15, 2024 | 144 | Filing |
| Mar 14, 2024 | 144 | Filing |
| Mar 8, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 7, 2024 | 144 | Filing |
| Mar 7, 2024 | 144 | Filing |